It’s been a catastrophic week for Valeant Pharmaceuticals (VRX). In the past few days, the $40 billion serial acquirer has been slashed to ribbons by a leading presidential candidate, seen its stock plunge by nearly half and been likened to Enron by a leading short-selling firm.

from Forbes – Tech http://ift.tt/1O5xCrq
via IFTTT